Leerink Partnrs Has Negative Outlook for RNA FY2025 Earnings

Avidity Biosciences, Inc. (NASDAQ:RNA) – Investment analysts at Leerink Partnrs cut their FY2025 earnings estimates for shares of Avidity Biosciences in a research report issued on Monday, November 10th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings of ($4.81) per share for the year, down from their prior forecast of ($4.47). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Avidity Biosciences’ current full-year earnings is ($2.89) per share. Leerink Partnrs also issued estimates for Avidity Biosciences’ Q4 2025 earnings at ($1.41) EPS, Q1 2026 earnings at ($1.49) EPS, Q2 2026 earnings at ($1.50) EPS, Q3 2026 earnings at ($1.49) EPS, Q4 2026 earnings at ($1.46) EPS, FY2026 earnings at ($5.96) EPS and FY2027 earnings at ($4.58) EPS.

RNA has been the topic of a number of other reports. Wolfe Research lowered Avidity Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 28th. Evercore ISI dropped their price target on shares of Avidity Biosciences from $70.00 to $65.00 and set an “outperform” rating for the company in a research note on Monday, September 22nd. HC Wainwright downgraded shares of Avidity Biosciences from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $87.00 to $72.00 in a research note on Monday, October 27th. Bank of America boosted their target price on shares of Avidity Biosciences from $56.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Avidity Biosciences in a research note on Wednesday, October 8th. Nine research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $69.24.

Avidity Biosciences Stock Performance

Shares of RNA opened at $70.82 on Thursday. Avidity Biosciences has a one year low of $21.51 and a one year high of $70.98. The stock has a 50-day moving average price of $52.01 and a 200 day moving average price of $40.92. The company has a market capitalization of $10.67 billion, a P/E ratio of -16.94 and a beta of 0.97.

Avidity Biosciences (NASDAQ:RNA) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.22). Avidity Biosciences had a negative net margin of 2,634.59% and a negative return on equity of 37.70%. The business had revenue of $12.50 million for the quarter, compared to analyst estimates of $1.80 million. The business’s revenue was up 420.8% compared to the same quarter last year.

Institutional Trading of Avidity Biosciences

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Avidity Biosciences by 42.9% during the 3rd quarter. Vanguard Group Inc. now owns 13,219,759 shares of the biotechnology company’s stock valued at $575,985,000 after purchasing an additional 3,971,457 shares during the period. Wellington Management Group LLP lifted its stake in Avidity Biosciences by 19.5% in the first quarter. Wellington Management Group LLP now owns 9,684,556 shares of the biotechnology company’s stock valued at $285,888,000 after buying an additional 1,578,459 shares during the last quarter. Norges Bank acquired a new position in shares of Avidity Biosciences during the second quarter valued at $28,261,000. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Avidity Biosciences in the 1st quarter worth about $22,765,000. Finally, Frazier Life Sciences Management L.P. bought a new stake in shares of Avidity Biosciences during the first quarter valued at approximately $15,498,000.

Insider Activity at Avidity Biosciences

In other news, insider Steven George Hughes sold 2,209 shares of the firm’s stock in a transaction dated Wednesday, October 22nd. The shares were sold at an average price of $47.54, for a total value of $105,015.86. Following the transaction, the insider directly owned 38,867 shares in the company, valued at approximately $1,847,737.18. This trade represents a 5.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Troy Edward Wilson sold 29,500 shares of the business’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $50.00, for a total transaction of $1,475,000.00. Following the sale, the director directly owned 54,425 shares of the company’s stock, valued at approximately $2,721,250. This represents a 35.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 154,438 shares of company stock valued at $7,588,537 in the last ninety days. 3.83% of the stock is owned by insiders.

About Avidity Biosciences

Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.